NASDAQ$OKUR
OnKure Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reneo Pharmaceuticals reported a net loss for the third quarter of 2021 and provided an update on its clinical programs.
Reneo Pharmaceuticals reported a net loss of $12.7 million, or $0.52 per share, for the three months ended September 30, 2021. The company's cash, cash equivalents and short-term investments totaled $157.7 million as of September 30, 2021.
- Initiated enrollment of STRIDE, a global, double-blind, randomized, placebo-controlled Phase 2b trial of REN001 in patients with PMM
- Completed enrollment in REN001-102, an open-label Phase 1b clinical trial in patients with LC-FAOD
- Appointed Ashley Hall as Chief Development Officer to lead nonclinical and clinical operations, global regulatory affairs, pharmaceutical development, and program management
- Received a notice of allowance from the USPTO for a composition of matter patent application covering the REN001 drug substance
Headline financials
Revenue & EPS history
Reneo Pharmaceuticals · Revenue · Quarterly
$458K
Forward guidance
Anticipated Upcoming Milestones include results of the Phase 1b clinical trial of REN001 in McArdle disease (1Q 2022), results of the Phase 1b clinical trial of REN001 in LC-FAOD (2Q 2022), and results of the FORWARD natural history study in LC-FAOD (2Q 2022).
Tailwinds
- Results of the Phase 1b clinical trial of REN001 in McArdle disease (1Q 2022)
- Results of the Phase 1b clinical trial of REN001 in LC-FAOD (2Q 2022)
- Results of the FORWARD natural history study in LC-FAOD (2Q 2022)
- Credit Suisse 30th Annual Healthcare Conference, November 8 - 11, 2021
- Jefferies 12th Annual London Healthcare Conference, November 16 – 19, 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+2.2%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+3.6%
Avg return
30 days after
52%
11 / 21 earnings
Positive
+21.2%
Q2 2025
Best reaction
-10.3%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.7% | -15.0% | -6.3% | |
| Q3 2025 | -5.5% | -2.5% | -3.2% | |
| Q2 2025 | +21.2% | +24.6% | +20.2% | |
| Q1 2025 | +12.5% | +7.5% | +21.0% | |
| Q4 2024 | +3.7% | +4.8% | -40.0% | |
| Q3 2024 | +3.2% | +1.8% | -16.7% | |
| Q2 2024 | +9.7% | +15.7% | +5.2% | |
| Q1 2024 | +2.4% | +3.0% | +0.6% | |
| Q4 2023 | +3.0% | +3.6% | +1.2% | |
| Q3 2023 | -0.9% | +5.6% | +21.1% | |
| Q2 2023 | -6.3% | -15.1% | +7.1% | |
| Q1 2023 | -1.4% | -0.9% | +79.3% | |
| Q4 2022 | -10.3% | -1.0% | +65.1% | |
| Q3 2022 | -3.0% | -8.6% | -35.4% | |
| Q2 2022 | -3.0% | +4.1% | +34.6% | |
| Q1 2022 | -5.9% | -10.8% | -28.2% | |
| Q4 2021 | -1.4% | -6.8% | -34.7% | |
| Q3 2021 | +14.8% | +5.7% | -13.2% | |
| Q2 2021 | +0.1% | -3.2% | +2.0% | |
| Q4 2020 | +7.5% | +2.9% | -2.3% | |
| Q1 2021 | +7.5% | +2.9% | -2.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro